Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGT-53 and Temozolomide in Recurrent Glioblastoma
NCT02340156Phase 2Terminated
- Sponsor
- SynerGene Therapeutics, Inc.
- Start
- Dec 2014
- Primary completion
- Nov 2018
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 2
01
Overview
A Phase 2 trial of SGT-53 in glioblastoma (GBM), sponsored by SynerGene Therapeutics, Inc.. Started Dec 2014; status: terminated.
02
Drugs
SGT-53
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02340156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340156.